These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

914 related items for PubMed ID: 33148997

  • 1. Brief Report: Weight Gain Following ART Initiation in ART-Naïve People Living With HIV in the Current Treatment Era.
    Ruderman SA, Crane HM, Nance RM, Whitney BM, Harding BN, Mayer KH, Moore RD, Eron JJ, Geng E, Mathews WC, Rodriguez B, Willig AL, Burkholder GA, Lindström S, Wood BR, Collier AC, Vannappagari V, Henegar C, Van Wyk J, Curtis L, Saag MS, Kitahata MM, Delaney JAC.
    J Acquir Immune Defic Syndr; 2021 Mar 01; 86(3):339-343. PubMed ID: 33148997
    [Abstract] [Full Text] [Related]

  • 2. The predicted risk of adverse pregnancy outcomes as a result of treatment-associated obesity in a hypothetical population receiving tenofovir alafenamide/emtricitabine/dolutegravir, tenofovir disoproxil fumarate/emtricitabine/dolutegravir or tenofovir disoproxil fumarate/emtricitabine/efavirenz.
    Asif S, Baxevanidi E, Hill A, Venter WDF, Fairlie L, Masenya M, Serenata C, Sokhela S, Chandiwana N.
    AIDS; 2021 Dec 15; 35(Suppl 2):S117-S125. PubMed ID: 34261099
    [Abstract] [Full Text] [Related]

  • 3. Weight Changes and Adverse Pregnancy Outcomes With Dolutegravir- and Tenofovir Alafenamide Fumarate-Containing Antiretroviral Treatment Regimens During Pregnancy and Postpartum.
    Hoffman RM, Brummel S, Ziemba L, Chinula L, McCarthy K, Fairlie L, Jean-Philippe P, Chakhtoura N, Johnston B, Krotje C, Nematadzira TG, Nakayiwa F, Ndyanabangi V, Hanley S, Theron G, Violari A, João E, Correa MD, Hofer CB, Navanukroh O, Aurpibul L, Nevrekar N, Zash R, Shapiro R, Stringer JSA, Currier JS, Sax P, Lockman S, IMPAACT 2010/VESTED Study Team .
    Clin Infect Dis; 2024 Jun 14; 78(6):1617-1628. PubMed ID: 38180851
    [Abstract] [Full Text] [Related]

  • 4. Body mass index increase and weight gain among people living with HIV-1 initiated on single-tablet darunavir/cobicistat/emtricitabine/tenofovir alafenamide or bictegravir/emtricitabine/tenofovir alafenamide in the United States.
    Emond B, Rossi C, Côté-Sergent A, Bookhart B, Anderson D, Lefebvre P, Lafeuille MH, Donga P.
    Curr Med Res Opin; 2022 Feb 14; 38(2):287-298. PubMed ID: 34812097
    [Abstract] [Full Text] [Related]

  • 5. Health care resource utilization and costs for treatment-experienced people with HIV switching or restarting antiretroviral regimens since 2018.
    Colson A, Chastek B, Gruber J, Majethia S, Zachry W, Mezzio D, Rock M, Anderson A, Cohen JP.
    J Manag Care Spec Pharm; 2024 Aug 14; 30(8):817-824. PubMed ID: 39088337
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Assessment of weight gain in adult patients living with HIV receiving first-line dolutegravir-based or efavirenz-based ART regimens in routine care clinics in Tshwane district, South Africa: An observational study.
    Sawry S, Ayalew K, Maimela G, Briggs-Hagen M, van Wyk-Heath M, Mthethwa S, Shai S, Mngomezulu NN, Tlhowe L, Achere-Darko J, Bedford J, Martin CE, Fairlie L, Imrie J.
    HIV Med; 2024 Jul 14; 25(7):826-839. PubMed ID: 38520085
    [Abstract] [Full Text] [Related]

  • 9. Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial.
    Venter WDF, Sokhela S, Simmons B, Moorhouse M, Fairlie L, Mashabane N, Serenata C, Akpomiemie G, Masenya M, Qavi A, Chandiwana N, McCann K, Norris S, Chersich M, Maartens G, Lalla-Edward S, Vos A, Clayden P, Abrams E, Arulappan N, Hill A.
    Lancet HIV; 2020 Oct 14; 7(10):e666-e676. PubMed ID: 33010240
    [Abstract] [Full Text] [Related]

  • 10. Weight and BMI Changes Following Initiation of Emtricitabine/Tenofovir Alafenamide Co-Formulated with Darunavir or Co-Administered with Dolutegravir in Overweight or Obese, ART-Naïve People Living with HIV-1.
    Donga P, Emond B, Rossi C, Bookhart BK, Lee J, Caron-Lapointe G, Wei F, Lafeuille MH.
    Clinicoecon Outcomes Res; 2023 Oct 14; 15():579-591. PubMed ID: 37521004
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in HIV late presenters.
    Corona D, Pérez-Valero I, Camacho A, Gutiérrez Liarte Á, Montero-Alonso M, Alemán MR, Ruiz-Seco P, Pérez González A, Riera M, Jarrin I, Rivero-Juárez A, Rivero A.
    Int J Antimicrob Agents; 2024 Jan 14; 63(1):107016. PubMed ID: 37890734
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV.
    Venter WDF, Moorhouse M, Sokhela S, Fairlie L, Mashabane N, Masenya M, Serenata C, Akpomiemie G, Qavi A, Chandiwana N, Norris S, Chersich M, Clayden P, Abrams E, Arulappan N, Vos A, McCann K, Simmons B, Hill A.
    N Engl J Med; 2019 Aug 29; 381(9):803-815. PubMed ID: 31339677
    [Abstract] [Full Text] [Related]

  • 15. Comparing the efficacy and safety of a first-line regimen with emtricitabine/tenofovir alafenamide fumarate plus either bictegravir or dolutegravir: Results from clinical practice.
    Ciccullo A, Baldin G, Borghi V, Oreni L, Lagi F, Fusco P, Giacomelli A, Torti C, Sterrantino G, Mussini C, Antinori S, Di Giambenedetto S.
    Int J Antimicrob Agents; 2024 Jan 29; 63(1):107040. PubMed ID: 37981074
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Brief Report: Weight Gain in Persons With HIV Switched From Efavirenz-Based to Integrase Strand Transfer Inhibitor-Based Regimens.
    Norwood J, Turner M, Bofill C, Rebeiro P, Shepherd B, Bebawy S, Hulgan T, Raffanti S, Haas DW, Sterling TR, Koethe JR.
    J Acquir Immune Defic Syndr; 2017 Dec 15; 76(5):527-531. PubMed ID: 28825943
    [Abstract] [Full Text] [Related]

  • 18. Mother-to-Child HIV Transmission With In Utero Dolutegravir vs. Efavirenz in Botswana.
    Davey S, Ajibola G, Maswabi K, Sakoi M, Bennett K, Hughes MD, Isaacson A, Diseko M, Zash R, Batlang O, Moyo S, Lockman S, Lichterfeld M, Kuritzkes DR, Makhema J, Shapiro R.
    J Acquir Immune Defic Syndr; 2020 Jul 01; 84(3):235-241. PubMed ID: 32195745
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 46.